ALK7 binding proteins and uses thereof
This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.
1 . An activin receptor-Like Kinase 7 (ALK7)-binding protein comprising a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 91 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 98,
wherein the protein binds to ALK7.
2 . The ALK7-binding protein of claim 1 , wherein the ALK7-binding protein is an antibody, wherein the antibody is a monoclonal antibody, a recombinant antibody, a humanized antibody, a chimeric antibody, a bi-specific antibody, a multi-specific antibody, or an ALK7-binding antibody fragment.
3 . The ALK7-binding protein of claim 2 , wherein the ALK7-binding antibody fragment is selected from a Fab fragment, a Fab′ fragment, a F(ab′) 2 fragment, a FV fragment, a diabody, or a single chain antibody molecule.
4 . The ALK7-binding protein of claim 2 , wherein the antibody further comprises a heavy chain immunoglobulin constant domain selected from:
(a) a human IgA constant domain;
(b) a human IgD constant domain;
(c) a human IgE constant domain;
(d) a human IgG1 constant domain;
(e) a human IgG2 constant domain;
(f) a human IgG3 constant domain;
(g) a human IgG4 constant domain; and
(h) a human IgM constant domain.
5 . The ALK7-binding protein of claim 2 , wherein the antibody further comprises a light chain immunoglobulin constant domain selected from the group consisting of:
(a) a human Ig kappa constant domain; and
(b) a human Ig lambda constant domain.
6 . The ALK7-binding protein of claim 2 , wherein the antibody further comprises a human IgG1 heavy chain constant domain and a human lambda light chain constant domain.
7 . An isolated ALK7-binding protein comprising a set of CDRs in which:
(i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:88;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:89;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:90;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:95;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO:96; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:97;
wherein the protein binds ALK7.